Twice-Yearly drug could beat river blindness
NCT ID NCT03876262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if taking moxidectin twice a year is safer and more effective than once a year for treating river blindness, a parasitic disease. About 323 people in the Democratic Republic of Congo will receive either moxidectin or ivermectin annually or biannually. The goal is to keep the skin free of the parasite that causes the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Democratic Republic of the Congo
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI app aims to help frontline workers diagnose neglected skin diseases
- New drug moxidectin put to the test against river blindness in massive safety trial
- New drug cocktails aim to beat river blindness
- New study aims to bring mental health support to people with neglected skin diseases in ghana
- Massive drug showdown: can a new pill beat river blindness for good?
- River blindness drug trial aims to find right dose for kids